Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Expanded Access Protocol EaP For Subjects Receiving Idecabtagene vicleucel That Is Nonconforming For commercial Release
Study Type: Treatment
Phase: N/A
NCTID: NCT04771078
Principal Investigator:
Alma Habib
A Phase III, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation ASCT in Participants with Newly Diagnosed Multiple Myeloma NDMM
Study Type: Treatment
Phase: III
NCTID: NCT05827016
Principal Investigator:
Al-Ola Abdallah
Long-term follow-up protocol for subjects treated with gene-modified GM T-cells
Study Type: Treatment
Phase: III
NCTID: NCT03435796
Principal Investigator:
Al-Ola Abdallah
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
Study Type: Treatment
Phase: II
NCTID: NCT06672146
Principal Investigator:
Kenneth Byrd
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone Dara-VCD Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Study Type: Treatment
Phase: III
NCTID: NCT06022939
Principal Investigator:
Muhammad Umair Mushtaq
Master Screening and Reassessment Protocol MSRP for Tier Advancement in the NCI myeloMATCH Clinical Trials
Study Type: Screening
Phase: N/A
NCTID: NCT05564390
Principal Investigator:
Tara Lin
A Measurable Residual Disease MRD Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy
Study Type: Treatment
Phase: II
NCTID: NCT05554393
Principal Investigator:
Heather Male
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin 7+3 vs Daunorubicin and Cytarabine Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and Daunorubicin and Cytarabine Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk Adverse Acute Myeloid Leukemia as Determined by MYELOMATCH; A MYELOMATCH CLINICAL TRIAL
Study Type: Treatment
Phase: II
NCTID: NCT05554406
Principal Investigator:
Tara Lin
A Phase Ib, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
Study Type: Treatment
Phase: I/II
NCTID: NCT06433947
Principal Investigator:
Al-Ola Abdallah
A Phase Ib trial of Teclistamab in Combination with Iberdomide for Relapsed/Refractory Multiple Myeloma
Study Type: Treatment
Phase: I
NCTID: NCT06465316
Principal Investigator:
Jeries Kort